Save Product
Product Details
Source
HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Cat. No. IGG-LY69) is a mouse monoclonal antibody produced from a hybridoma generated by fusion of SP2/0 myeloma cells with mouse B lymphocytes.
Antibody Type
Hybridoma Monoclonal
Clone
6F11C8
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Reactivity
Human
Immunogen
Human-IgG-Fc
Conjugate
HRP conjugated
Specificity
This product can react with the Fc portion of Human IgG1/ IgG2/ IgG3/ IgG4 and multiple engineered variants, including: Human IgG1 (N297A), Human IgG1 (L234A/L235A), Human IgG1 (M252Y/S254T/T256E), Human IgG1 (L234F/L235E/P331S), Human IgG1 (S239D/I332E), Human IgG1 (S298A/E333A/K334A), Human IgG1 (T307A/E380A/N434A), Human IgG2 (A330S/P331S), Human IgG2 (P331S), Human IgG4 (S108P), and Human IgG4 (S228P/L235E).
Application
ApplicationRecommended Use / PerformanceELISA1:800-1:8000Cross Verification
This antibody recognizes all four human IgG isotypes (IgG1, IgG2, IgG3, and IgG4) and multiple engineered variants, including: Human IgG1 (N297A), Human IgG1 (L234A/L235A), Human IgG1 (M252Y/S254T/T256E), Human IgG1 (L234F/L235E/P331S), Human IgG1 (S239D/I332E), Human IgG1 (S298A/E333A/K334A), Human IgG1 (T307A/E380A/N434A), Human IgG2 (A330S/P331S), Human IgG2 (P331S), Human IgG4 (S108P), and Human IgG4 (S228P/L235E).
Weak cross-reactivity with cynomolgus IgG was observed by ELISA, whereas no reactivity to mouse IgG isotypes (IgG1, IgG2a, IgG2b) was detected.Purification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 6 months after reconstitution;
- 2-8°C for 2-3 weeks under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Human TNF-alpha Protein, His Tag (Cat. No. TNA-H5228) at 2 μg/mL (100 μL/well) can bind Human Monoclonal Anti-TNF-alpha antibody, Human IgG1 (16H5) (Cat. No. TNA-AM494) when detected by HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8),mAb (Cat. No. IGG-LY69) dilute at 1:10000 (0.0842μg/ml) (QC tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Immunoglobulin G
- Category：
- Approved Drugs：
1 Details
- Drugs in Clinical Trials：
7 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
